First Tissue-Agnostic Drug Approval Issued [News in Brief]

Pembrolizumab OK'd for mismatch repair–deficient or microsatellite instability–high solid tumors.

from Cancer via ola Kala on Inoreader http://ift.tt/2rYeuqC
via IFTTT